Although significant progress has been made in the treatment of childhood acute lymphoblastic leukemia (ALL) the prognosis following relapse is still poor. Additional prognostic indicators are needed to better target treatment and thereby improve the treatment of these patients. We have previously demonstrated an association between poor outcome and CD44v6 expression in a heterogeneous cohort of patients. Others have shown by microarray analysis that CD44 expression in diagnostic samples is linked with relapse risk. In this study, we examined CD44 and CD44v6 protein expression by flow cytometry and CD44v6 mRNA expression by quantitative RT-PCR in diagnostic samples from 97 pediatric patients with ALL. We found that CD44 protein expression was associated with disease relapse and was independent of age and WCC. In contrast, high CD44v6 expression was not associated with relapse. These findings may assist in the process of refining prognostic groups for children with ALL.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/10428190701861660 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Preparation and identification of a fluorescent probe with CsPbBrperovskite quantum dots and CD44v6 specific peptide for gastric cancer imaging.
Nanotechnology
October 2024
The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an Jiaotong University, Xi'an 710049, People's Republic of China.
Since the sensitivity and accuracy of traditional detection for early gastric cancer diagnosis are still insufficient, it is significant to continuously optimize the optical molecular imaging detection technology based on an endoscopic platform. The signal intensity and stability of traditional chemical fluorescent dyes are low, which hinders the clinical application of molecular imaging detection technology. This work developed a probe based on perovskite quantum dots (PQDs) and peptide ligands.
View Article and Find Full Text PDFCo-expression of CD44v6 and MMP2 predicts lung metastasis and unfavorable prognosis in osteosarcoma.
Future Oncol
October 2024
Department of orthopedic, The Second Hospital of Tangshan, No.21, Jianshe North Road, Tangshan 063000, China.
To evaluate the prognostic significance of CD44 variant v6 (CD44v6) and matrix metalloproteinases 2 (MMP2) expression in patients with surgically resected osteosarcoma. CD44v6 and MMP2 expression were immunohistochemically detected in 113 primary osteosarcoma patients at our institute between 2001 and 2019. Both CD44v6 and MMP2 were independent predictors for metastasis-free and overall survival.
View Article and Find Full Text PDFA paclitaxel-hyaluronan conjugate (ONCOFID-P-B™) in patients with BCG-unresponsive carcinoma in situ of the bladder: a dynamic assessment of the tumor microenvironment.
J Exp Clin Cancer Res
April 2024
Immunology and Molecular Oncology Diagnostics, Veneto Institute of Oncology IOV-IRCCS, Via Gattamelata 64, 35128, Padova, Italy.
Background: The intravesical instillation of the paclitaxel-hyaluronan conjugate ONCOFID-P-B™ in patients with bacillus Calmette-Guérin (BCG)-unresponsive bladder carcinoma in situ (CIS; NCT04798703 phase I study), induced 75 and 40% of complete response (CR) after 12 weeks of intensive phase and 12 months of maintenance phase, respectively. The aim of this study was to provide a detailed description of the tumor microenvironment (TME) of ONCOFID-P-B™-treated BCG-unresponsive bladder CIS patients enrolled in the NCT04798703 phase I study, in order to identify predictive biomarkers of response.
Methods: The composition and spatial interactions of tumor-infiltrating immune cells and the expression of the most relevant hyaluronic acid (HA) receptors on cancer cells, were analyzed in biopsies from the 20 patients enrolled in the NCT04798703 phase I study collected before starting ONCOFID-P-B™ therapy (baseline), and after the intensive and the maintenance phases.
CD44v6, STn & O-GD2: promising tumor associated antigens paving the way for new targeted cancer therapies.
Front Immunol
November 2023
Biomedical Research Institute I+12, University Hospital "12 de Octubre", Madrid, Spain.
Targeted therapies are the state of the art in oncology today, and every year new Tumor-associated antigens (TAAs) are developed for preclinical research and clinical trials, but few of them really change the therapeutic scenario. Difficulties, either to find antigens that are solely expressed in tumors or the generation of good binders to these antigens, represent a major bottleneck. Specialized cellular mechanisms, such as differential splicing and glycosylation processes, are a good source of neo-antigen expression.
View Article and Find Full Text PDFCD44v6 downregulation as a prognostic factor for distant recurrence in resected stage I lung adenocarcinomas.
Clin Exp Med
December 2023
Department of General Thoracic Surgery, Faculty of Medicine, Kagawa University, Kagawa, Japan.
CD44 and CD44 variant isoforms have been reported as contributing factors to cancer progression. In this study, we aimed to assess whether CD44 and its variant isoforms were correlated with the prognostic factors for distant metastasis in stage I lung adenocarcinomas using tissue microarray and immunohistochemistry. In this single-center retrospective study, we analyzed the data of 490 patients with stage I lung adenocarcinoma resected between 1999 and 2016.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!